Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.

Theranostics - 1 Jan 2024

Zhu Qianru, Zhang Ruonan, Gu Xiaoqing, Zhao Ziming, Gao Quan, Chen Min, Wu Qibiao, Xie Tian, Sui Xinbing

Abstract excerpt

Rationale : the proto-oncogene KRAS is frequently mutated in colorectal cancer (CRC), leading to inherent resistance against monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), such as cetuximab. Therefore, addressing the primary resistance and expanding the indications for target therapy have become critical challenges. Methods : the screening of a natural product library against KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Mice, Nude

Share to Phenols

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39310106
DOI: 10.7150/thno.97180
PMCID: PMC11413778

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.PMID 39310106Read ↗

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSemantic proximity Read ↗

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.Semantic proximity Read ↗

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

Monensin as potential drug for treatment of SLeX-positive tumorsSemantic proximity Read ↗

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.Semantic proximity Read ↗

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factorsSemantic proximity Read ↗

Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.Semantic proximity Read ↗

Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice.Semantic proximity Read ↗

Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem CellsSemantic proximity Read ↗

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.Semantic proximity Read ↗

Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.